Session 1095: Immune surveillance & vaccine trials

Date: 4 February 2004, Time: 14:00 - 16:00
Location: Room 1

Oral Presentations

Time	Number	Title / Authors / Affiliations
14:00	350	Induction of CD8+ T cell responses to melanoma with tumor-antigen expressing canary pox vectors NL Berinstein^a, B Uger^a, S Elias^a,b, S Verma^c, S Burdette-Radoux^d ^aAventis Pasteur, Toronto, Ont, ^bToronto-Sunnybrook Regional Cancer Centre, Toronto, Ont, ^cOttawa-Regional Cancer Centre, Ottawa, Ont, ^dMcGill University Health Centre, Montreal, Quebec, Canada
14:20	351	Complement component C3 as a molecular adjuvant for the immune response: a candidate for new vaccine strategy M-B Villiers PhD, B Cherif, PN Marche PhD, CL Villiers PhD DRDC/ICH/INSERM U548, CEA-G, 17 rue des Martyrs, 38054 GRENOBLE Cedex 09, FRANCE
14:35	352	Preliminary results of a phase I/II clinical trial of a prostate cancer vaccine containing PSA, IL-2 and GM-CSF JF Head PhD, RL Elliott MD PhD Elliott-Hailey-Head Breast Cancer Research and Treatment Center, Baton Rouge, LA, United States
14:50	353	Preventive peptide vaccine for colorectal cancer metastases P Sinibaldi-Vallebona PhD^a, G Rasi MD^b, P Pierimarchi MD^b, M Zonfrillo^a,b, E Guarino^b, E Garaci^a (a) Department of Experimental Medicine and Biochemical Sciences – University of Rome “Tor Vergata” Via Montpellier, 1 –00133 Rome; (b) Institute of Neurobiology and Molecular Medicine, (INeMM), National Research Council, Via Fosso del Cavaliere, 100 – 00133 Rome; Italy
15:05	354	Circulating BCR-ABL specific CD8+ cells are detectable in chronic myeloid leukaemia patients and healthy subjects RE Clark MD^a, NM Butt MB ChB^a, L Wang MD^a, H Abu-Eisha^b, SE Christmas PhD^b ^aDepartment of, Haematology and, LIVERPOOL L7 8XP, United Kingdom, ^bImmunology, Duncan Building, University of Liverpool, LIVERPOOL L7 8XP, United Kingdom